Send us a text This week on IPWatchdog Unleashed, we panel discussion that took place on October 27 as a part of our annual life sciences program. Initially styled as a conversation about how artificial intelligence is transforming life sciences, it becomes quickly apparent that the conversation was not going to be limited to the life sciences sector but instead was a robust discussion about what any innovative company should consider when considering the adoption of AI tools. Indeed, the dis...
All content for IPWatchdog Unleashed is the property of Gene Quinn and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text This week on IPWatchdog Unleashed, we panel discussion that took place on October 27 as a part of our annual life sciences program. Initially styled as a conversation about how artificial intelligence is transforming life sciences, it becomes quickly apparent that the conversation was not going to be limited to the life sciences sector but instead was a robust discussion about what any innovative company should consider when considering the adoption of AI tools. Indeed, the dis...
Patents, Patients and Progress: A Conversation with Henry Hadad
IPWatchdog Unleashed
45 minutes
3 weeks ago
Patents, Patients and Progress: A Conversation with Henry Hadad
Send us a text This week on IPWatchdog Unleashed we have an interesting and entertaining conversation between Gene Quinn, President & CEO of IPWatchdog, Inc., and Henry Hadad, Chief IP Counsel and Deputy General Counsel at Bristol Myers Squibb. The conversation is wide ranging. They discuss the complexities and challenges patent laws are creating for medical diagnostics and cancer treatment. Henry shares his journey from law school to becoming a key player in the biopharmaceutical industr...
IPWatchdog Unleashed
Send us a text This week on IPWatchdog Unleashed, we panel discussion that took place on October 27 as a part of our annual life sciences program. Initially styled as a conversation about how artificial intelligence is transforming life sciences, it becomes quickly apparent that the conversation was not going to be limited to the life sciences sector but instead was a robust discussion about what any innovative company should consider when considering the adoption of AI tools. Indeed, the dis...
